Research programme: injectable insulin formulations - AntriaBio

Drug Profile

Research programme: injectable insulin formulations - AntriaBio

Alternative Names: AB 101; AB 102; InsuLAR; insulin sustained-release

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator PR Pharmaceuticals
  • Developer AntriaBio
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 28 Sep 2016 AntriaBio has patent protection for ProPhase™ technology in the US, Australia, India, Japan and Europe (AntriaBio 10-K, September 2016).
  • 28 Sep 2016 AntriaBio has patents pending for ProPhase™ technology in the Canada, Brazil, China and Hong Kong (AntriaBio 10-K, September 2016).
  • 17 Nov 2015 AntriaBio receives patent allowance for AB 101 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top